GoHealth (GOCO) Research & Development (2019 - 2026)

GoHealth has disclosed Research & Development across 8 years of filings, most recently posting $7.7 million for Q1 2026.

• Research & Development for Q1 2026 came in at $7.7 million, down 85.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$16.4 million (down 105.47% YoY), and the FY2025 annual result was $34.9 million, down 84.31% from the prior year.
• Research & Development came in at $7.7 million for Q1 2026 at GoHealth, up from -$60.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $193.5 million in Q4 2024 to a low of -$90.7 million in Q4 2023.
• The 5-year median for Research & Development is $26.2 million (2025), against an average of $30.1 million.
• Across the five-year window, Research & Development jumped 715.79% in 2022 and tumbled 887.27% in 2023, its largest moves.
• GoHealth's Research & Development stood at $11.5 million in 2022, then sank by 887.27% to -$90.7 million in 2023, then soared by 313.26% to $193.5 million in 2024, then plunged by 131.12% to -$60.2 million in 2025, then surged by 112.72% to $7.7 million in 2026.
• The last three Research & Development figures came in at $7.7 million (Q1 2026), -$60.2 million (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.